June 7 (Reuters) - TherapeuticsMD Inc TXMD.O :
* THERAPEUTICSMD AND THERAMEX ENTER INTO EXCLUSIVE LICENSE AND SUPPLY AGREEMENT TO COMMERCIALIZE BIJUVA™ AND IMVEXXY® OUTSIDE THE UNITED STATES
* THERAPEUTICSMD INC - AGREEMENT LEVERAGES THERAMEX'S EXTENSIVE WOMEN'S HEALTH CAPABILITIES AND INFRASTRUCTURE TO BENEFIT OF MENOPAUSAL WOMEN OUTSIDE OF U.S.
* THERAPEUTICSMD INC - THERAPEUTICSMD TO RECEIVE EUR 14 MILLION AS AN UPFRONT FEE
* THERAPEUTICSMD INC - IS ELIGIBLE TO RECEIVE UP TO EUR 29.5 MILLION IN REGULATORY AND SALES MILESTONE PAYMENTS, AS WELL AS A ROYALTY ON NET SALES
* THERAPEUTICSMD INC - THERAPEUTICSMD IS ALSO ENTITLED TO RECEIVE ROYALTY PAYMENTS ON NET SALES OF BIJUVA AND IMVEXXY IN LICENSED TERRITORIES
* THERAPEUTICSMD - CO ENTITLED TO RECEIVE ROYALTY PAYMENTS ON NET SALES OF BIJUVA AND IMVEXXY IN LICENSED TERRITORIES
* THERAPEUTICSMD-THERAMEX WILL BE RESPONSIBLE FOR CONDUCTING REGULATORY AND COMMERCIAL ACTIVITIES RELATED TO BIJUVA AND IMVEXXY IN LICENSED TERRITORIES
* THERAPEUTICSMD INC - THERAMEX WILL HAVE EXCLUSIVE COMMERCIALIZATION RIGHTS FOR BIJUVA AND IMVEXXY OUTSIDE U.S., EXCLUDING CANADA AND ISRAEL